The edition · Neurology
APOE changes what a plasma p-tau217 result means, and distal occlusions get their own syndrome
Genotype modifies both the risk and the timing that a p-tau217 concentration predicts; menopausal hormone therapy tracks with less Alzheimer pathology at autopsy; autoimmune disease clusters in the two years before myasthenia; and ASTCT regrades immune effector cell neurotoxicity.
The edition in brief
A pooled analysis of seven prospective cohorts and 8,582 older adults asked whether APOE genotype adds prognostic information to a plasma p-tau217 concentration. It does. Higher p-tau217 was associated with prevalent cognitive impairment (odds ratio 1.77) and with incident impairment (hazard ratio 1.41 per standard deviation), but the association was consistently stronger in APOE-e4 carriers than non-carriers, and each standard deviation increase shortened time to impairment by 24% in carriers against 13% in non-carriers. Survival curves separated three to four years after the blood test and before symptoms. A narrative synthesis argues that distal and medium vessel occlusion stroke should be treated as a distinct syndrome rather than a failed extension of large vessel thrombectomy, after randomised trials in broadly defined populations showed no functional benefit and numerically more intracranial haemorrhage. Two cohort datasets found estrogen-only menopausal hormone therapy associated with lower odds of raised Alzheimer pathology at autopsy (odds ratio 0.65, 95% CI 0.48 to 0.88) and of clinical dementia diagnosis (0.61, 0.55 to 0.67) — associations only, from self-reported use. A Korean nationwide study of 8,355 patients with myasthenia gravis and 83,550 matched controls found autoimmune disease twice as frequent in the preceding decade and four times as frequent in the two years before diagnosis, strongest for lupus, Sjogren syndrome and autoimmune thyroid disease. A pearl covers last known well. The edition closes with the updated ASTCT consensus grading, which now defines non-ICANS neurological toxicities including parkinsonism, cranial nerve palsies and polyneuropathies alongside revised criteria for cytokine release syndrome and ICANS.
APOE genotype changes both the risk and the timing a p-tau217 result predicts
Interpret a plasma p-tau217 result alongside APOE status, and agree what will be disclosed before the sample is taken.
Distal and medium vessel occlusion is a different syndrome, not a smaller version of the same one
Keep declining routine thrombectomy for distal occlusions, but document the anatomy and deficit properly — the neutral trials were not asking a single question.
Menopausal hormone therapy tracked with less Alzheimer pathology at autopsy
Ask about past hormone therapy in a cognitive history, but do not offer it as dementia prevention.
Autoimmune disease clustered in the two years before myasthenia gravis was diagnosed
Fatigable weakness in a patient with an existing autoimmune diagnosis warrants acetylcholine receptor antibodies sooner than you would otherwise send them.
Last known well is not when the symptoms were noticed
Write both times in the notes, with the source — the number recorded first will be the one every later decision uses.
ASTCT extends its toxicity grading beyond ICANS to parkinsonism and neuropathy
Grade non-ICANS neurotoxicity — parkinsonism, cranial nerve palsies, polyneuropathy — under the updated criteria rather than stretching ICANS to fit.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free